Expression and prognosis of GNG5 in lower-grade glioma using public database. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Tan, Xiaohui; Zhou, Huandi; Hou, Liubing; Li, Haonan; Liu, Junling; Li, Yuehong; Xue, Xiaoying
• Is Part Of: All life. Volume 15:Issue 1(2022)
• Page Start: 1101
• Page End: 1116
• Publication Date: 2022-12-31
• Subjects: Lower-grade glioma -- prognosis -- biomarker -- GNG5; Life sciences -- Periodicals; Biology -- Periodicals; Electronic journals; Periodicals; 570.5
• DOI: 10.1080/26895293.2022.2131636
• Languages: English
• ISSNs: 2689-5293

Abstract

Abstract : Background: Glioma is the most common primary brain tumor, but its therapeutic effect is not very ideal up to now. The point of this study was to recognize the potential gene involved in lower-grade glioma (LGG) and to promote the treatment and prognosis for LGG patients. Method: During the investigation, we first studied the differential expression and the survival analysis of GNG5 in patients with glioma, LGG, and GBM, respectively. Then, independent prognostic analysis, the clinical relevance characteristics and the differential expressed genes (DEGs) were also evaluated. In addition, Metascape and GSEA analyses were carried out to achieve potential mechanism. Co-expression and immune infiltration analysis were finally conducted. Results: The results indicated that GNG5 as an independent prognostic indicator was negatively associated with the overall survival of LGG patients. Metascape and GSEA analyses showed that GNG5 may participate in complement and coagulation cascades pathway. The co-expression analysis was concluded that GNG5 was positively correlated with the following factors: C4B, PLAU, C1R, C1QC, C4A, SERPINA1, C1QB, CFI, C3. Conclusions: This study demonstrated that the highly expression of GNG5 in LGG may lead to poor prognosis. Besides, our research also revealed that GNG5 may be a promising immune-related biomarker for LGG patients.